Clinical data from 127 cases of HER2+ early BC patients who recieved trastuzumab treatment indicated that the high-circCDYL2-expressing HER2+-BC tumors were significantly associated with larger tumour size, increased lymphatic metastasis and higher Ki67 index (Table 1). Here, MKI67 is linked to breast cancer.